Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
NCT02073656
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
335
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C Virus
HIV
Interventions
DRUG:
LDV/SOF
DRUG:
RBV
Sponsor
Gilead Sciences